Skip to main content
. 2013 Nov 23;4(12):2419–2429. doi: 10.18632/oncotarget.1572

Figure 3. I-BET762 treatment modulates expression of MYC and c-Myc-driven pathways in prostate cancer cell lines.

Figure 3

A, GSEA enrichment plot showing down-regulation of a MYC signature in LNCaP cells treated with 0.5 µM I-BET762 for 24 hours. Normalized enrichment score (NES) and FDR q value are indicated. B, Western blot analysis of c-Myc expression in the indicated cell lines following treatment with a titration of I-BET762 for three days. C, Western blot analysis of c-Myc expression following 3 days treatment with 1µM I-BET762, control siRNA, or MYC siRNA. D, Analysis of cell proliferation in I-BET762 or siRNA-treated LNCaP cells 6 days post-treatment. Data is presented as percent of untreated control cells, and represents the mean +/− SDM for two independent biological replicates.